This study found that IL-1 alpha inhibits the growth of cultured human hair follicles and hair fibers, suggesting a potential role in inflammatory hair loss conditions like alopecia areata.
19 citations
,
September 2008 in “Journal of Cellular Physiology”
This article explores potential mechanisms of acneiform skin eruptions linked to EGFR inhibition in cancer patients, focusing on EGFR's role in controlling IL-1-dependent inflammation at hair follicles, but reports no clinical results.
15 citations
,
October 2014 in “The journal of investigative dermatology/Journal of investigative dermatology”
This study suggests that erlotinib exacerbates inflammation in a mouse model of skin disease and that IL-1 inhibition could mitigate skin-related side effects of EGFR inhibitors.
Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.
Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.